Unlocking the Potential of Cell Delivery Agents

Link Technologies will present a poster at the Annual Meeting of the Oligonucleotide Therapeutic Society
By: Link Technologies
Sept. 27, 2013 - PRLog -- Link Technologies Ltd (http://www.linktech.co.uk/), an ISO 9001:2008 certified specialist oligonucleotide reagent manufacturer, will be presenting a poster at the upcoming 9th Annual Meeting of the Oligonucleotide Therapeutic Society (http://www.oligotherapeutics.org/) (OTS), 6-8 October, Naples, Italy. The poster entitled ‘New Potential Oligonucleotide Delivery Reagents’, details how Link Technologies’ novel modifiers can enable the enhanced delivery of oligos for therapeutic effect. Inspired by their existing collection of lipophilic modifiers (http://www.linktech.co.uk/products/modifiers/hydrophobic_group_cholesterol_palmitate_modification), which have been proven to enhance cell penetration, Link Technologies has developed this new collection of modified phosphoramidites, and are inviting collaborative partners to help discover their full application potential. At OTS, Dr Catherine McKeen, Technical Manager at Link Technologies, will be on-hand throughout the poster presentation sessions to provide further information and answer any questions.

For more information on Link Technologies and our enabling lipophilic modifiers for cell delivery, please attend our poster presentation at OTS or request a free copy of our 2013/14 Product Guide (http://linktech.wufoo.eu/forms/link-technologies-product-...). Providing comprehensive information for scientists working with modified oligos, including validated protocols and supporting application notes, the new product guide is an ideal go-to resource for oligonucleotide chemistry.

Alternatively, please visit the website at www.linktech.co.uk or follow us on Twitter: @linktechdna (https://twitter.com/#!/linktechdna).
Source:Link Technologies
Email:***@alto-marketing.com Email Verified
Tags:Link Technologies
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share